The Facts

Download Data

Venture Capital Deals: Healthcare

Venture capital deals in the healthcare sector in Q2 2013 have shown an increase of 66% in terms of aggregate value compared to Q1 2013. Gemma Morris explores the make-up of healthcare deals since 2008.








Fig. 3: Proportion of Number and Aggregate Value of Healthcare Deals by Industry, 2008 - H1 2013




Source: Preqin Venture Deals Analyst

Fig. 2: Proportion of Number of Healthcare Deals by Stage, 2008 -H1 2013



Source: Preqin Venture Deals Analyst

Fig. 4: Number and Aggregate Value of Healthcare Deals as a Proportion of All Venture Capital Deals Globally, 2008 - H1 2013



Source: Preqin Venture Deals Analyst

Fig. 5: Top Five Venture Capital Healthcare Deals Globally by Deal Size, H1 2013

Firm	Stage	Deal Date	Deal Size (\$mn)	Investors	Location
Intrexon Corporation	Series F/Round 6	May-13	150	Third Security	US
ShanghaiMed Healthcare, Inc.	Growth Capital/ Expansion	Apr-13	100	Goldman Sachs Merchant Banking Division, Government of Singapore Investment Corporation (GIC)	China
Alvine Pharmaceuticals	Unspecified Round	May-13	70	Abbott Biotech Ventures	US
Proteus Digital Health	Series F/Round 6	May-13	63	Novartis Venture Funds, Oracle Corporation	US
PTC Therapeutics, Inc.	Unspecified Round	Mar-13	60	Adage Capital Management, Brookside Group, Celgene, Delphi Ventures, HBM Partners, Jennison Associates, Longwood Fund, Novo A/S, The Column Group, Vulcan Capital	US

Source: Preqin Venture Deals Analyst

Subscriber Quicklink:

Subscribers to Preqin's Venture Deals Analyst can click here to access 9,979 venture capital deals in the healthcare industry. View detailed information on financing rounds and locations to see who the most active fund managers are in the healthcare space.

Not yet a subscriber? For more information, or to register for a demonstration, please visit:

www.preqin.com/vcdeals



2013 Preqin Investor Network Global Alternatives Report

The Report is the most comprehensive review of the alternatives industry aimed exclusively at institutional investors ever undertaken. It includes in-depth analysis on:



- Methods of investing in alternative assets.
- **Performance** of alternative assets, including industry benchmarks.
- Alternative **funds open for investment**, including league tables.
- **Consistent performing** managers, and top performing funds.
- Terms and conditions, funds of funds, secondary market, and more.

Plus hear from some of the industry's most significant voices, including David Rubenstein, Josh Lerner, and Luke Ellis.

For more information, or to download a free copy, please visit:

www.preqin.com/PIN2013